{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T23:22:33Z","timestamp":1787440953126,"version":"build-2736575974"},"reference-count":123,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006701","name":"Umm Al-Qura University","doi-asserted-by":"publisher","award":["26UQU4310387GSSR04"],"award-info":[{"award-number":["26UQU4310387GSSR04"]}],"id":[{"id":"10.13039\/501100006701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.biopha.2026.119585","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T10:15:55Z","timestamp":1779704155000},"page":"119585","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Integrative co-delivery platforms for paclitaxel: Advancing synergistic breast cancer therapy"],"prefix":"10.1016","volume":"200","author":[{"given":"Waleed H.","family":"Almalki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119585_bib1","article-title":"Personalizing therapies over the course of hormone receptor-positive\/HER2-negative metastatic breast cancer","volume":"76","author":"Singareeka Raghavendra","year":"2026","journal-title":"Ca. Cancer J. Clin."},{"key":"10.1016\/j.biopha.2026.119585_bib2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.annonc.2024.10.824","article-title":"Estrogens and breast cancer","volume":"36","author":"Kim","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2026.119585_bib3","first-page":"1","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2026.119585_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103862","article-title":"Survival feature and trend of female breast cancer: A comprehensive review of survival analysis from cancer registration data","volume":"79","author":"Tang","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.biopha.2026.119585_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejpb.2017.02.020","article-title":"Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy","volume":"115","author":"Eloy","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.biopha.2026.119585_bib6","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1021\/acs.langmuir.5c05243","article-title":"Paclitaxel-Loaded Nanoarchaeosomes: An Innovative Strategy for Targeted Breast Cancer Treatment","volume":"42","author":"Ariraman","year":"2026","journal-title":"Langmuir"},{"key":"10.1016\/j.biopha.2026.119585_bib7","article-title":"Paclitaxel resistance in breast cancer: Current challenges and recent advanced therapeutic strategies","volume":"43","author":"Abouzeid","year":"2025","journal-title":"Cancer Treat. Res. Commun."},{"key":"10.1016\/j.biopha.2026.119585_bib8","first-page":"1","article-title":"Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial","author":"Gion","year":"2025","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2026.119585_bib9","doi-asserted-by":"crossref","DOI":"10.1080\/14728222.2025.2537416","article-title":"Improving therapeutic strategies for triple-negative breast cancer: synergistic effects of DKC1 inhibition and paclitaxel","author":"Vilarullo","year":"2025","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.biopha.2026.119585_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2024.1415191","article-title":"Dendritic polylysine co-delivery of paclitaxel and siAXL enhances the sensitivity of triple-negative breast cancer chemotherapy","volume":"12","author":"Wan","year":"2024","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.biopha.2026.119585_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123209","article-title":"Ratiometric codelivery of Paclitaxel and Baicalein loaded nanoemulsion for enhancement of breast cancer treatment","volume":"643","author":"Yadav","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119585_bib12","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.3390\/molecules23112906","article-title":"Co-delivery of gemcitabine and paclitaxel in cRGD-modified long circulating nanoparticles with asymmetric lipid layers for breast cancer treatment","volume":"23","author":"Zhang","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2026.119585_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.145766","article-title":"Exosome-mediated communication in pancreatic cancer: from molecular crosstalk to clinical translation","volume":"320","author":"Khan","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.biopha.2026.119585_bib14","article-title":"Hyaluronic acid functionalized liposomes for co-delivery of paclitaxel and ursolic acid for enhanced efficacy against triple negative breast cancer","volume":"104","author":"Sharma","year":"2025","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.biopha.2026.119585_bib15","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1021\/acsabm.4c00027","article-title":"Fabrication of PEGylated SPIONs-Loaded Niosome for Codelivery of Paclitaxel and Trastuzumab for Breast Cancer Treatment: In Vivo Study","volume":"7","author":"Masoumi Godgaz","year":"2024","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.biopha.2026.119585_bib16","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.5c00473","article-title":"Translational Insights into Stimuli-Responsive Magnetic Nanoparticles for Breast Cancer Treatment","author":"Khan","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2026.119585_bib17","doi-asserted-by":"crossref","first-page":"10537","DOI":"10.1021\/acsanm.5c01289","article-title":"Liposome-Based Codelivery of AgFe2O4\/TiO2 and Paclitaxel for Enhanced Breast Cancer Photothermal Chemotherapy","volume":"8","author":"Liu","year":"2025","journal-title":"ACS Appl. Nano Mater."},{"key":"10.1016\/j.biopha.2026.119585_bib18","article-title":"Paclitaxel for breast cancer therapy: A review on effective drug combination modalities and nano drug delivery platforms","volume":"95","author":"Kaveh Zenjanab","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.biopha.2026.119585_bib19","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.colsurfb.2016.01.032","article-title":"Co-loaded paclitaxel\/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy","volume":"141","author":"Eloy","year":"2016","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.biopha.2026.119585_bib20","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.2147\/IJN.S126310","article-title":"Low-density lipoprotein-coupled micelles with reduction and ph dual sensitivity for intelligent co-delivery of paclitaxel and siRNA to breast tumor","volume":"12","author":"Zhu","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2026.119585_bib21","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s13233-023-00240-8","article-title":"Efficient and controllable co-delivery of paclitaxel and curcumin from fucoidan-pluronic F127 nanogel for synergistic breast cancer treatment","volume":"32","author":"Nguyen","year":"2024","journal-title":"Macromol. Res."},{"key":"10.1016\/j.biopha.2026.119585_bib22","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/1061186X.2022.2091578","article-title":"ABC transporters in breast cancer: their roles in multidrug resistance and beyond","volume":"30","author":"Modi","year":"2022","journal-title":"J. Drug Target"},{"key":"10.1016\/j.biopha.2026.119585_bib23","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s12282-020-01210-z","article-title":"Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer","volume":"28","author":"Nedeljkovi\u0107","year":"2021","journal-title":"Breast Cancer"},{"key":"10.1016\/j.biopha.2026.119585_bib24","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.3390\/ijms22063199","article-title":"Pleiotropic Roles of ABC Transporters in Breast Cancer","volume":"22","author":"He","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119585_bib25","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-024-01990-4","article-title":"Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer","volume":"23","author":"Kundu","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2026.119585_bib26","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the chou-talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2026.119585_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173919","article-title":"Synergistic potential of dual andrographolide and melatonin targeting of metastatic colon cancer cells: Using the Chou-Talalay combination index method","volume":"897","author":"Banerjee","year":"2021","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119585_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.eurpolymj.2024.112800","article-title":"Carbon nanotube-mediated platinum-based drug delivery for the treatment of cancer: Advancements and future perspectives","volume":"206","author":"Sameer Khan","year":"2024","journal-title":"Eur. Polym. J."},{"key":"10.1016\/j.biopha.2026.119585_bib29","article-title":"Co-delivery paclitaxel and IR783 as nanoparticles for potentiated chemo-photothermal-immunotherapy of triple-negative breast cancer","volume":"33","author":"Huang","year":"2025","journal-title":"Mater. Today Bio."},{"key":"10.1016\/j.biopha.2026.119585_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2018.10.032","article-title":"Co-delivery of paclitaxel and cisplatin in poly(2-oxazoline) polymeric micelles: Implications for drug loading, release, pharmacokinetics and outcome of ovarian and breast cancer treatments","volume":"192","author":"Wan","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2026.119585_bib31","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1007\/s13346-021-01105-2","article-title":"Ratiometric co-delivery of doxorubicin and paclitaxel prodrug by remote-loading liposomes for the treatment of triple-negative breast cancer","volume":"12","author":"Wang","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.biopha.2026.119585_bib32","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.2147\/IJN.S249144","article-title":"Co-delivery of paclitaxel and doxorubicin by ph-responsive prodrug micelles for cancer therapy","volume":"15","author":"Jiang","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2026.119585_bib33","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jpha.2020.04.005","article-title":"Design and preparation of a new multi-targeted drug delivery system using multifunctional nanoparticles for co-delivery of siRNA and paclitaxel","volume":"11","author":"Nasab","year":"2021","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.biopha.2026.119585_bib34","doi-asserted-by":"crossref","DOI":"10.1080\/09205063.2025.2510441","article-title":"Nanostructured solid lipid for Paclitaxel and Kaempferol co-delivery as a novel synergistic approach for breast cancer","author":"Dewangan","year":"2025","journal-title":"J. Biomater. Sci. Polym. Ed."},{"key":"10.1016\/j.biopha.2026.119585_bib35","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2174\/1389557520999201214234421","article-title":"Resistance to Intervention: Paclitaxel in Breast Cancer","volume":"21","author":"Dan","year":"2020","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.biopha.2026.119585_bib36","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1021\/acs.molpharmaceut.9b01148","article-title":"Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance","volume":"17","author":"Zhong","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2026.119585_bib37","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.biopha.2016.08.061","article-title":"Anti-tumor efficiency of paclitaxel and DNA when co-delivered by pH responsive ligand modified nanocarriers for breast cancer treatment","volume":"83","author":"Yu","year":"2016","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2026.119585_bib38","doi-asserted-by":"crossref","first-page":"966","DOI":"10.2174\/1567201819666220401095923","article-title":"Curcumin and Paclitaxel Co-loaded Heparin and Poloxamer P403 Hybrid Nanocarrier for Improved Synergistic Efficacy in Breast Cancer","volume":"19","author":"Nguyen","year":"2022","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.biopha.2026.119585_bib39","article-title":"Understanding the theranostic potential of quantum dots in cancer management","volume":"36","author":"Khan","year":"2023","journal-title":"Mater. Today Commun."},{"key":"10.1016\/j.biopha.2026.119585_bib40","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1039\/D4TB01090F","article-title":"Maximising efficacy in HER2-positive breast cancer: immunoliposomal co-delivery of miR155 inhibitor and paclitaxel for targeted therapy","volume":"13","author":"Chaudhari","year":"2025","journal-title":"J. Mater. Chem. B."},{"key":"10.1016\/j.biopha.2026.119585_bib41","unstructured":"Y. Shariati, F.S. Kahrizsangi, N. Hozhabrossadati, D. Naseri, M. Ebrahimi, Evaluate the Clinical Outcome of Nanoparticle Albumin-bound Paclitaxel on Breast Cancer Treatment: A Systematic Review and Meta-analysis, (2022)."},{"key":"10.1016\/j.biopha.2026.119585_bib42","first-page":"1","article-title":"Therapeutic evaluation of paclitaxel co-loaded PLGA nanoparticles with imatinib, protamine-imatinib, and gefitinib: comparative in vitro studies in MDA-MB-231 breast cancer cells and in vivo investigations in rats","author":"Laxane","year":"2025","journal-title":"Naunyn. Schmiede Arch. Pharm."},{"key":"10.1016\/j.biopha.2026.119585_bib43","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ijpharm.2013.06.017","article-title":"Synergistic co-delivery of doxorubicin and paclitaxel using multi-functional micelles for cancer treatment","volume":"454","author":"Duong","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119585_bib44","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1021\/acs.molpharmaceut.9b00209","article-title":"Co-Delivery of Paclitaxel by a Capsaicin Prodrug Micelle Facilitating for Combination Therapy on Breast Cancer","volume":"16","author":"Lan","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2026.119585_bib45","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-023-02677-x","article-title":"Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial","volume":"30","author":"Jiang","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2026.119585_bib46","doi-asserted-by":"crossref","first-page":"6762","DOI":"10.1039\/C7TB01510K","article-title":"Hybrid nanoparticles coated with hyaluronic acid lipoid for targeted co-delivery of paclitaxel and curcumin to synergistically eliminate breast cancer stem cells","volume":"5","author":"Yang","year":"2017","journal-title":"J. Mater. Chem. B."},{"key":"10.1016\/j.biopha.2026.119585_bib47","article-title":"Nanoparticles for co-delivery of paclitaxel and curcumin to overcome chemoresistance against breast cancer","volume":"79","author":"Lin","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.biopha.2026.119585_bib48","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1470-2045(23)00051-7","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial","volume":"24","author":"Tolaney","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2026.119585_bib49","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1016\/j.biomaterials.2014.03.012","article-title":"Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core\u2013shell nanoparticles","volume":"35","author":"Feng","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2026.119585_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119875","article-title":"Co-delivery of paclitaxel and curcumin by biodegradable polymeric nanoparticles for breast cancer chemotherapy","volume":"589","author":"Xiong","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119585_bib51","doi-asserted-by":"crossref","DOI":"10.1080\/09205063.2025.2525668","article-title":"Dual drug delivery of Paclitaxel and Curcumin via hyaluronic acid functionalized nanoparticles for improved breast cancer therapy","author":"Praveena","year":"2025","journal-title":"J. Biomater. Sci. Polym. Ed."},{"key":"10.1016\/j.biopha.2026.119585_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.855294","article-title":"Design and Characterization of Paclitaxel-Loaded Polymeric Nanoparticles Decorated With Trastuzumab for the Effective Treatment of Breast Cancer","volume":"13","author":"Sakhi","year":"2022","journal-title":"Front. Pharm."},{"key":"10.1016\/j.biopha.2026.119585_bib53","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1016\/j.apsb.2025.04.006","article-title":"Targeting stem-property and vasculogenic mimicry for sensitizing paclitaxel therapy of triple-negative breast cancer by biomimetic codelivery","volume":"15","author":"Wu","year":"2025","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.biopha.2026.119585_bib54","first-page":"1","article-title":"Advancing triple-negative breast cancer treatment through peptide decorated solid lipid nanoparticles for paclitaxel delivery","volume":"15","author":"Rahdari","year":"2025","journal-title":"Sci. Rep. 2025 151."},{"key":"10.1016\/j.biopha.2026.119585_bib55","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.biomaterials.2017.09.013","article-title":"pH multistage responsive micellar system with charge-switch and PEG layer detachment for co-delivery of paclitaxel and curcumin to synergistically eliminate breast cancer stem cells","volume":"147","author":"Yang","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2026.119585_bib56","doi-asserted-by":"crossref","first-page":"30369","DOI":"10.18632\/oncotarget.16153","article-title":"A multifunctional lipid nanoparticle for co-delivery of paclitaxel and curcumin for targeted delivery and enhanced cytotoxicity in multidrug resistant breast cancer cells","volume":"8","author":"Baek","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2026.119585_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-025-00734-x","article-title":"Development and validation of a functional ex vivo paclitaxel and eribulin sensitivity assay for breast cancer, the REMIT assay","volume":"11","author":"Komar","year":"2025","journal-title":"Npj Breast Cancer"},{"key":"10.1016\/j.biopha.2026.119585_bib58","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/08982104.2015.1070174","article-title":"Liposomal formulation for co-delivery of paclitaxel and lapatinib, preparation, characterization and optimization","volume":"26","author":"Ravar","year":"2016","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.biopha.2026.119585_bib59","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1080\/10717544.2019.1580797","article-title":"Dual-functionalized liposome by co-delivery of paclitaxel with sorafenib for synergistic antitumor efficacy and reversion of multidrug resistance","volume":"26","author":"Lei","year":"2019","journal-title":"Drug Deliv."},{"key":"10.1016\/j.biopha.2026.119585_bib60","doi-asserted-by":"crossref","first-page":"8069","DOI":"10.1039\/D4NR05418K","article-title":"Nanoassemblies of the redox paclitaxel prodrug with the natural active ingredient dihydroartemisinin for therapy of breast cancer","volume":"17","author":"Rui","year":"2025","journal-title":"Nanoscale"},{"key":"10.1016\/j.biopha.2026.119585_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.141754","article-title":"\u03b1v\u03b23 integrin aptamer functionalized pH-responsive lipid polymer hybrid nanoparticles for targeted co-delivery of paclitaxel and tamoxifen","volume":"306","author":"Narwade","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.biopha.2026.119585_bib62","first-page":"487","article-title":"PEGylated Liposomes of Disulfiram and Paclitaxel: A Promising Chemotherapeutic Combination Against Chemoresistant Breast Cancer","volume":"18","author":"Said Suliman","year":"2025","journal-title":"Pharm"},{"key":"10.1016\/j.biopha.2026.119585_bib63","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.1021\/acsanm.5c00803","article-title":"Antitumor Efficacy of a Complex Liposomal Formulation for Co-Delivery of Paclitaxel Palmitate and Adriamycin","volume":"8","author":"Wu","year":"2025","journal-title":"ACS Appl. Nano Mater."},{"key":"10.1016\/j.biopha.2026.119585_bib64","article-title":"Co-delivery of paclitaxel and regorafenib by F127\/TPGS mixed micelles for triple negative breast cancer treatment","volume":"86","author":"Nezhadi","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.biopha.2026.119585_bib65","first-page":"1","article-title":"Combination Therapy using Co-encapsulated Resveratrol and Paclitaxel in Liposomes for Drug Resistance Reversal in Breast Cancer Cells in vivo","volume":"6","author":"Meng","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119585_bib66","doi-asserted-by":"crossref","first-page":"11539","DOI":"10.2147\/IJN.S488369","article-title":"Enhanced in vivo Stability and Antitumor Efficacy of PEGylated Liposomes of Paclitaxel Palmitate Prodrug","volume":"19","author":"Wu","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2026.119585_bib67","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ijpharm.2019.02.009","article-title":"Ratiometric co-encapsulation and co-delivery of doxorubicin and paclitaxel by tumor-targeted lipodisks for combination therapy of breast cancer","volume":"560","author":"Feng","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119585_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2018.10.032","article-title":"Co-delivery of paclitaxel and cisplatin in poly(2-oxazoline) polymeric micelles: Implications for drug loading, release, pharmacokinetics and outcome of ovarian and breast cancer treatments","volume":"192","author":"Wan","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2026.119585_bib69","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.actbio.2017.08.027","article-title":"Concurrently suppressing multidrug resistance and metastasis of breast cancer by co-delivery of paclitaxel and honokiol with pH-sensitive polymeric micelles","volume":"62","author":"Wang","year":"2017","journal-title":"Acta Biomater."},{"key":"10.1016\/j.biopha.2026.119585_bib70","doi-asserted-by":"crossref","first-page":"6805","DOI":"10.1021\/acsbiomaterials.3c01332","article-title":"Collagen-Binding Nanoparticles for Paclitaxel Encapsulation and Breast Cancer Treatment","volume":"9","author":"Passos","year":"2023","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.biopha.2026.119585_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217785","article-title":"Efficacy and safety of inetetamab plus pertuzumab and nab-paclitaxel as neoadjuvant therapy for HER2+ breast cancer: A single-arm multicenter phase II clinical trial","volume":"627","author":"Zuo","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2026.119585_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2025.114663","article-title":"Repeated sequential administration of pegylated emulsion of SU5416 and liposomal paclitaxel enhances anti-tumor effect in 4T1 breast cancer-bearing mice","volume":"209","author":"Maruyama","year":"2025","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.biopha.2026.119585_bib73","doi-asserted-by":"crossref","first-page":"6133","DOI":"10.2147\/IJN.S488545","article-title":"Nanoemulsions Based Therapeutic Strategies: Enhancing Targeted Drug Delivery against Breast Cancer Cells","volume":"20","author":"Izadiyan","year":"2025","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2026.119585_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.145766","article-title":"Exosome-mediated communication in pancreatic cancer: From molecular crosstalk to clinical translation","volume":"320","author":"Khan","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.biopha.2026.119585_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103819","article-title":"Unravelling the potential of mitochondria-targeted liposomes for enhanced cancer treatment","volume":"29","author":"Khan","year":"2024","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2026.119585_bib76","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/10717544.2021.2018523","article-title":"Co-delivery of paclitaxel (PTX) and docosahexaenoic acid (DHA) by targeting lipid nanoemulsions for cancer therapy","volume":"29","author":"Li","year":"2022","journal-title":"Drug Deliv."},{"key":"10.1016\/j.biopha.2026.119585_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.eurpolymj.2024.112800","article-title":"Carbon nanotube-mediated platinum-based drug delivery for the treatment of cancer: Advancements and future perspectives","volume":"206","author":"Sameer Khan","year":"2024","journal-title":"Eur. Polym. J."},{"key":"10.1016\/j.biopha.2026.119585_bib78","first-page":"1","article-title":"Preparation and anti-triple-negative breast cancer cell effect of a nanoparticle for the codelivery of paclitaxel and gemcitabine","volume":"18","author":"Yang","year":"2023","journal-title":"Discov. Nano"},{"key":"10.1016\/j.biopha.2026.119585_bib79","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.actbio.2021.07.029","article-title":"Co-delivery of paclitaxel and STAT3 siRNA by a multifunctional nanocomplex for targeted treatment of metastatic breast cancer","volume":"134","author":"Luo","year":"2021","journal-title":"Acta Biomater."},{"key":"10.1016\/j.biopha.2026.119585_bib80","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.2147\/IJN.S517753","article-title":"Platelet Membrane-Coated Poly (Lactic-Co-Glycolic Acid) Nanoparticles as a Targeting Drug Delivery System for Multidrug-Resistant Breast Cancer","volume":"20","author":"Song","year":"2025","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2026.119585_bib81","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s13346-023-01415-7","article-title":"Exploring the synergistic behavior of paclitaxel and vorinostat upon co-loading in albumin nanoparticles for breast cancer management","volume":"14","author":"Abhang","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.biopha.2026.119585_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118806","article-title":"Co-delivery of epirubicin and paclitaxel using an estrone-targeted PEGylated liposomal nanoparticle for breast cancer","volume":"573","author":"Tang","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119585_bib83","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.2147\/IJN.S126310","article-title":"Low-density lipoprotein-coupled micelles with reduction and ph dual sensitivity for intelligent co-delivery of paclitaxel and siRNA to breast tumor","volume":"12","author":"Zhu","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2026.119585_bib84","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.2147\/IJN.S313339","article-title":"Smart polymeric nanoparticles with pH-responsive and Peg-detachable properties (II): Co-delivery of paclitaxel and VEGF siRNA for synergistic breast cancer therapy in mice","volume":"16","author":"Jin","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2026.119585_bib85","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejps.2016.06.017","article-title":"Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells","volume":"92","author":"Zhang","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2026.119585_bib86","article-title":"Local delivery of paclitaxel and celecoxib by bionic tracheal stent to enhance chemo-immunotherapy for malignant tracheal stenosis","author":"Wang","year":"2026","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.biopha.2026.119585_bib87","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2026.119585_bib88","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3390\/cancers17010050","article-title":"Dose-Limiting Toxicities of Paclitaxel in Breast Cancer Patients: Studying Interactions Between Pharmacokinetics, Physical Activity, and Body Composition\u2014A Protocol for an Observational Cohort Study","volume":"17","author":"De Nys","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119585_bib89","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/jnci\/djab004","article-title":"Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study","volume":"113","author":"Emens","year":"2021","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.biopha.2026.119585_bib90","article-title":"Nanoparticles for co-delivery of paclitaxel and curcumin to overcome chemoresistance against breast cancer","volume":"79","author":"Lin","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.biopha.2026.119585_bib91","article-title":"Co-delivery systems of paclitaxel prodrug for targeted synergistic therapy of breast cancer","volume":"69","author":"Yin","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.biopha.2026.119585_bib92","doi-asserted-by":"crossref","unstructured":"Co-delivery of paclitaxel and gemcitabine via a self-assembling nanoparticle for targeted treatment of breast cancer - RSC Advances (RSC Publishing) DOI:10.1039\/C9RA00276F, (n.d.). \u3008https:\/\/pubs.rsc.org\/en\/content\/articlehtml\/2019\/ra\/c9ra00276f\u3009 (accessed September 24, 2025).","DOI":"10.1039\/C9RA00276F"},{"key":"10.1016\/j.biopha.2026.119585_bib93","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.3109\/10837450.2014.965323","article-title":"Pluronic F127 polymeric micelles for co-delivery of paclitaxel and lapatinib against metastatic breast cancer: preparation, optimization and in vitro evaluation","volume":"20","author":"Kelishady","year":"2015","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.biopha.2026.119585_bib94","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijpharm.2017.06.071","article-title":"Co-delivery of paclitaxel and anti-survivin siRNA via redox-sensitive oligopeptide liposomes for the synergistic treatment of breast cancer and metastasis","volume":"529","author":"Chen","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119585_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119875","article-title":"Co-delivery of paclitaxel and curcumin by biodegradable polymeric nanoparticles for breast cancer chemotherapy","volume":"589","author":"Xiong","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119585_bib96","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.actbio.2021.07.029","article-title":"Co-delivery of paclitaxel and STAT3 siRNA by a multifunctional nanocomplex for targeted treatment of metastatic breast cancer","volume":"134","author":"Luo","year":"2021","journal-title":"Acta Biomater."},{"key":"10.1016\/j.biopha.2026.119585_bib97","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/08982104.2015.1070174","article-title":"Liposomal formulation for co-delivery of paclitaxel and lapatinib, preparation, characterization and optimization","volume":"26","author":"Ravar","year":"2016","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.biopha.2026.119585_bib98","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/jbm.a.36410","article-title":"Combinational drug delivery using nanocarriers for breast cancer treatments: A review","volume":"106","author":"Olov","year":"2018","journal-title":"J. Biomed. Mater. Res. Part A."},{"key":"10.1016\/j.biopha.2026.119585_bib99","doi-asserted-by":"crossref","first-page":"30369","DOI":"10.18632\/oncotarget.16153","article-title":"A multifunctional lipid nanoparticle for co-delivery of paclitaxel and curcumin for targeted delivery and enhanced cytotoxicity in multidrug resistant breast cancer cells","volume":"8","author":"Baek","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2026.119585_bib100","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1021\/acs.molpharmaceut.9b00209","article-title":"Co-Delivery of Paclitaxel by a Capsaicin Prodrug Micelle Facilitating for Combination Therapy on Breast Cancer","volume":"16","author":"Lan","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2026.119585_bib101","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1021\/acs.molpharmaceut.5b00536","article-title":"Co-delivery of Pirarubicin and Paclitaxel by Human Serum Albumin Nanoparticles to Enhance Antitumor Effect and Reduce Systemic Toxicity in Breast Cancers","volume":"12","author":"Yi","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2026.119585_bib102","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.biomaterials.2015.05.022","article-title":"Co-delivery of hydrophobic paclitaxel and hydrophilic AURKA specific siRNA by redox-sensitive micelles for effective treatment of breast cancer","volume":"61","author":"Yin","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2026.119585_bib103","first-page":"356","article-title":"Cobalt Oxide Nanoparticles in Cancer Therapy: A Review of Design, Drug Delivery Potential, and Translational Prospects","volume":"16","author":"Khan","year":"2026","journal-title":"BioNanoScience 2026 166"},{"key":"10.1016\/j.biopha.2026.119585_bib104","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.biomaterials.2008.10.062","article-title":"The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles","volume":"30","author":"Lee","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2026.119585_bib105","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1021\/acs.molpharmaceut.8b00217","article-title":"Codelivery of Paclitaxel and Everolimus at the Optimal Synergistic Ratio: A Promising Solution for the Treatment of Breast Cancer","volume":"15","author":"Houdaihed","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2026.119585_bib106","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.actbio.2017.08.027","article-title":"Concurrently suppressing multidrug resistance and metastasis of breast cancer by co-delivery of paclitaxel and honokiol with pH-sensitive polymeric micelles","volume":"62","author":"Wang","year":"2017","journal-title":"Acta Biomater."},{"key":"10.1016\/j.biopha.2026.119585_bib107","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.nano.2016.07.016","article-title":"Calcium phosphate-polymer hybrid nanoparticles for enhanced triple negative breast cancer treatment via co-delivery of paclitaxel and miR-221\/222 inhibitors","volume":"13","author":"Zhou","year":"2017","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.biopha.2026.119585_bib108","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jddst.2018.09.017","article-title":"Cationic liposomes for co-delivery of paclitaxel and anti-Plk1 siRNA to achieve enhanced efficacy in breast cancer","volume":"48","author":"Bulbake","year":"2018","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.biopha.2026.119585_bib109","first-page":"1","article-title":"RSL3 induces ferroptosis by activating the NF-\u03baB signalling pathway to enhance the chemosensitivity of triple-negative breast cancer cells to paclitaxel","volume":"15","author":"Yuan","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119585_bib110","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.mayocp.2020.01.035","article-title":"Paclitaxel-Coated Balloons and Stents for Lower Extremity Peripheral Arterial Disease Interventions: A Regulatory Perspective for the Practicing Clinician","volume":"95","author":"Vallabhajosyula","year":"2020","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.biopha.2026.119585_bib111","doi-asserted-by":"crossref","unstructured":"R.S. Gaspar, H.F. Florindo, L.C. Silva, M.A. Videira, M.L. Corvo, B.F. Martins, B. Silva-Lima, Regulatory Aspects of Oncologicals: Nanosystems Main Challenges, (2014) 425\u2013452. https:\/\/doi.org\/10.1007\/978-3-319-08084-0_15.","DOI":"10.1007\/978-3-319-08084-0_15"},{"key":"10.1016\/j.biopha.2026.119585_bib112","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/B978-0-443-33548-8.00008-2","article-title":"Regulatory aspects of liposome-based drug delivery systems","author":"Abishek","year":"2026","journal-title":"Fundam. Ther. Appl. Liposomes"},{"key":"10.1016\/j.biopha.2026.119585_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124212","article-title":"Advancements in liposomal formulations: A comprehensive exploration of industrial production techniques","volume":"658","author":"Sameer Khan","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119585_bib114","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.2147\/IJN.S259432","article-title":"Synergistic combination of sodium aescinate-stabilized, polymer-free, twin-like nanoparticles to reverse paclitaxel resistance","volume":"15","author":"Li","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2026.119585_bib115","doi-asserted-by":"crossref","first-page":"30369","DOI":"10.18632\/oncotarget.16153","article-title":"A multifunctional lipid nanoparticle for co-delivery of paclitaxel and curcumin for targeted delivery and enhanced cytotoxicity in multidrug resistant breast cancer cells","volume":"8","author":"Baek","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2026.119585_bib116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-021-00800-z","article-title":"A paclitaxel and microRNA-124 coloaded stepped cleavable nanosystem against triple negative breast cancer","volume":"19","author":"Chen","year":"2021","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.biopha.2026.119585_bib117","first-page":"135","article-title":"Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial","volume":"4","author":"Li","year":"2024","journal-title":"J. Natl. Cancer Cent."},{"key":"10.1016\/j.biopha.2026.119585_bib118","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2147\/IJN.S372961","article-title":"Paclitaxel Has a Reduced Toxicity Profile in Healthy Rats After Polymeric Micellar Nanoparticle Delivery","volume":"18","author":"Lu","year":"2023","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2026.119585_bib119","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1016\/j.xphs.2017.05.027","article-title":"Coloaded Nanoparticles of Paclitaxel and Piperlongumine for Enhancing Synergistic Antitumor Activities and Reducing Toxicity","volume":"106","author":"Liu","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2026.119585_bib120","doi-asserted-by":"crossref","first-page":"30369","DOI":"10.18632\/oncotarget.16153","article-title":"A multifunctional lipid nanoparticle for co-delivery of paclitaxel and curcumin for targeted delivery and enhanced cytotoxicity in multidrug resistant breast cancer cells","volume":"8","author":"Baek","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2026.119585_bib121","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1007\/s10311-020-01061-2","article-title":"Inorganic nanoparticles for natural product delivery: a review","volume":"18","author":"Meena","year":"2020","journal-title":"Environ. Chem. Lett."},{"key":"10.1016\/j.biopha.2026.119585_bib122","article-title":"Paclitaxel and curcumin co-loaded mixed micelles: Improving in vitro efficacy and reducing toxicity against Abraxane\u00ae","volume":"62","author":"Riedel","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.biopha.2026.119585_bib123","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.ijbiomac.2020.03.060","article-title":"Drug-binding albumins forming stabilized nanoparticles for co-delivery of paclitaxel and resveratrol: In vitro\/in vivo evaluation and binding properties investigation","volume":"153","author":"Zhao","year":"2020","journal-title":"Int. J. Biol. Macromol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226006219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226006219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T22:59:06Z","timestamp":1787439546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226006219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":123,"alternative-id":["S0753332226006219"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119585","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrative co-delivery platforms for paclitaxel: Advancing synergistic breast cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119585","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119585"}}